Cubist Systematic Strategies, LLC Kezar Life Sciences, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $105,215 - $139,376	45,548 Added 18.66%	289,691 $709,000
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $698,240 - $1.63 Million	223,080 Added 1059.11%	244,143 $764,000
Q4 2022 Feb 14, 2023	SELL	$6.39 - $8.8 $339,673 - $467,781	-53,157 Reduced 71.62%	21,063 $148,000
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $162,476 - $218,601	-20,335 Reduced 21.51%	74,220 $639,000
Q2 2022 Aug 15, 2022	BUY	$4.58 - $17.13 $373,796 - $1.4 Million	81,615 Added 630.72%	94,555 $782,000
Q1 2022 May 16, 2022	BUY	$12.3 - $18.33 $4,231 - $6,305	344 Added 2.73%	12,940 $215,000
Q4 2021 Feb 14, 2022	BUY	$7.44 - $16.72 $93,714 - $210,605	12,596 New	12,596 $211,000
Q3 2020 Nov 16, 2020	SELL	$4.36 - $5.5 $64,946 - $81,928	-14,896 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.6 - $7.75 $53,625 - $115,444	14,896 New	14,896 $77,000
Q2 2019 Aug 14, 2019	SELL	$7.09 - $21.9 $29,607 - $91,454	-4,176 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.83 - $23.75 $70,282 - $99,180	4,176 New	4,176 $74,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $430M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.